Efficacy and Safety of the Anti-COVID-19 Antibody SA55 for Injection in Patients With Hematological Disorders Who Are Persistently Positive for COVID-19

NACompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

January 12, 2023

Primary Completion Date

April 3, 2024

Study Completion Date

April 3, 2024

Conditions
Hematological DisordersCOVID-19
Interventions
BIOLOGICAL

Anti-COVID-19 Antibody SA55 for Injection

After the subjects are successfully screened, according to the group they belong to, they will be given the corresponding drug by intramuscular injection once (the dose of SA55 injection for subjects 40kg and above in the test group is 600mg (4ml), and the dose of SA55 injection for subjects in the test group below 40kg is 300mg (2ml), the subjects in the placebo group who are 40kg and above are injected with 4ml of placebo, and those in the test group under 40kg are injected with 2ml of placebo.The injection is allowed in both deltoid muscle of the upper arm or the buttocks muscle.

Trial Locations (1)

100070

Beijing Boren Hospital, Beijing

All Listed Sponsors
lead

Beijing Boren Hospital

OTHER